A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Inclusion Criteria

• Patients ≥18 years of age.
• Patients must have a histologic diagnosis of GIST.
• Patients must have GIST that has progressed on or have intolerance to at least 2 lines of prior TKI therapies.
• Patients must have an Eastern Cooperative Oncology Group performance score of ≤ 2.
• If a female of childbearing potential, must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements.
• Adequate organ and bone marrow function.

Exclusion Criteria

• Received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose.
• Prior treatment with ripretinib.
• Patients who have had prior repaglinide treatment within 14 days prior to Cycle 1 Day 1.
• History or presence of clinically relevant cardiovascular abnormalities.
• Gastrointestinal abnormalities including but not limited to:
• inability to take oral medication,
• malabsorption syndromes,
• requirement for intravenous alimentation.
• Patients who have type 1 or type 2 diabetes.